Lanteri-Minet, M.
Fabre, R.
Martin, C.
Pradat, K.
Alchaar, A.
Bozzolo, E.
Duchene, M. L.
Van Obberghen, E. K.
Donnet, A.
Fontaine, D.
Article History
Received: 15 August 2023
Accepted: 16 October 2023
First Online: 8 November 2023
Declarations
:
: This observational study did not require the authorization of an ethics committee. This study was part of the FHU InovPain database clinical research program which received authorization from the National Commission on Informatics and Liberty (<i>Commission Nationale de information et des Libertés—CNIL</i> / CIL register no. 278 dated 11/09/2017). Patients were included only after signing two separate written informed consents: the first enabling their personal data to be transmitted to Novartis Pharma SAS for validation of their eligibility in the compassionate program allowing them to benefit from free erenumab, and the second allowing the data collected in the FHU InovPain database to be used for clinical research purposes.
: Not applicable.
: LMM received personal fees for consultancy activities from: Abbvie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer, Teva.FR had no conflict of interest.MC received personnal fees for consultancy activities from Lilly, LundbeckPK received personal fees for consultancy activities from Eli Lilly and LundbeckAH received personal fees for consultancy activities from Eli Lilly and NovartisBE had received personal fees for consultancy activities from AbbvieDML had no confict of interestsVOE had received personal fees for consultancy activities from AbbvieDA received personal fees for consultancy activities from Abbvie/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer, TevaFD had no conlict of interest.FHU InvoPain received research support from Eli-Lilly, Lundbeck, Novartis, Pfizer and Teva.